ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma-Reference-Cited by-同舟云学术

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

Published:2014-11 Issue:5 Volume:26 Page:682-694
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Bresler Scott C.,Weiser Daniel A.,Huwe Peter J.,Park Jin H.,Krytska Kateryna,Ryles Hannah,Laudenslager Marci,Rappaport Eric F.,Wood Andrew C.,McGrady Patrick W.,Hogarty Michael D.,London Wendy B.,Radhakrishnan Ravi,Lemmon Mark A.,Mossé Yaël P.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference48 articles.

1. A method and server for predicting damaging missense mutations;Adzhubei;Nat. Methods,2010

2. Chromosome 1p and 11q deletions and outcome in neuroblastoma;Attiyeh;N. Engl. J. Med.,2005

3. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors;Bagci;Cancer Lett.,2012

4. PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations;Bendl;PLoS Comput. Biol.,2014

5. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors;Bossi;Biochemistry,2010

Cited by 307 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

2. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

3. Targeting pediatric solid tumors in the new era of RNA therapeutics;Critical Reviews in Oncology/Hematology;2024-08

4. Molecular Alterations in Pediatric Solid Tumors;Clinics in Laboratory Medicine;2024-06

5. Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531;Pediatric Blood & Cancer;2024-05-31